Search results
Showing 1 to 15 of 18 results for niraparib
Evidence-based recommendations on niraparib (Zejula) for treating relapsed, platinum-sensitive high-grade serous epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
Evidence-based recommendations on niraparib (Zejula) for maintenance treatment of advanced (FIGO stages 3 and 4) high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
NICE is unable to make a recommendation about the use in the NHS of niraparib (Zejula) with abiraterone acetate and prednisone for untreated hormone-relapsed metastatic prostate cancer in adults. This is because Johnson & Johnson Innovative Medicine did not provide an evidence submission.
Show all sections
Sections for TA1032
Evidence-based recommendations on rucaparib (Rubraca) for the maintenance treatment of relapsed platinum-sensitive high-grade epithelial, ovarian, fallopian tube or primary peritoneal cancer that has completely or partially responded to platinum-based chemotherapy in adults.
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of BRCA mutation-positive advanced ovarian, fallopian tube or peritoneal cancer after response to first-line platinum-based chemotherapy in adults.
Evidence-based recommendations on olaparib (Lynparza) with bevacizumab (Avastin) for high-grade epithelial ovarian, fallopian tube or primary peritoneal cancer in adults.
Awaiting development [GID-TA11365] Expected publication date: TBC
Awaiting development [GID-TA11558] Expected publication date: TBC
Evidence-based recommendations on olaparib (Lynparza) for maintenance treatment of relapsed, platinum-sensitive ovarian, fallopian tube or peritoneal cancer after 2 or more courses of platinum-based chemotherapy in adults.
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Managed access allows patients to access promising new treatments that would otherwise not be recommended because it is too uncertain whether the treatment is cost-effective.
Breast cancer (HER2-negative, BRCA-mutation, unresectable) - niraparib [ID1084]
Discontinued [GID-TA11178]
Awaiting development [GID-TA11406] Expected publication date: TBC
Awaiting development [GID-TA11367] Expected publication date: TBC